*NEED MEDSCAPE LOGIN AND PASSWORD TO ACCESS THIS STORY*
A recent study suggests that treatment with natalizumab (Tysabri, Biogen Idec) beyond 2 years compared with switching to other drugs can control relapsing-remitting multiple sclerosis (RRMS) with adequate safety.
The longer a patient with RRMS is treated with natalizumab, the greater the risk of developing progressive multifocal leukoencephalopathy (PML), especially in patients who are infected with JC virus after 2 years of monthly treatments.
Click here to read more
